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Background: Benzimidazole derivatives are structurally bioisosteres of naturally occurring nucleotides, which makes
them compatible with biopolymers of living systems. This property gives benzimidazole a biological and clinical
importance. In the last decade, this class of compounds has been reported to possess anti-allergic, anti-diabatic,
anti-HIV, anti-hypertensive, anti-inflammatory, anti-mycobacterial, anti-oxidant, anti-protozoal, and anti-viral
properties. The researchers are now interested to explore their potential as anti-cancer agents. In the present study,
an effort was made to further explore this area of research. Furthermore, in order to increase the solubility and
efficacy of these heterocycles, the interest is now shifted to the salts of these compounds. With this background,
we planned to synthesize a series of meta-xylyl linked bis-benzimidazolium salts to assess their anti-proliferation
efficacy on human colon cancer cell line (HCT 116).
Results: A number of N-alkylbenzimidazoles were synthesized by reactions of benzimidazole with alkyl halides
(i-PrBr, PrBr, EthBr, Pent-2-ylBr, BuBr, BenzCl, HeptBr). The subsequent treatment of the resulting
N-alkylbenzimidazoles with 1,3-(bromomethylene)benzene afforded corresponding bis-benzimidazolium salts.
All synthesized compounds were characterized by spectroscopic techniques (Additional file 1: NMR & FT-IR) and
microanalysis. Molecular structures of selected compounds were established through single crystal x-ray diffraction
studies. All the compounds were assessed for their anti-proliferation test on human colorectal cancer cell line
(HCT 116). Results showed that the compounds exhibited dose dependent cytotoxicity towards the colon cancer
cells with IC50 ranges between 0.1 to 17.6 μM. The anti-proliferation activity of all compounds was more
pronounced than that of standard reference drug 5-flourouracil (IC50 =19.2 μM).
Conclusions: All the synthesized bis-benzimidazolium salts showed potential anticancer activity. Out of them, some
of these salts showed IC50 value as low as 0.1–0.2 μM. Based on the results it can be concluded that, the
bis-benzimidazolium salts could probably be the potential source of chemotherapeutic drugs.* Correspondence: rosenani@usm.my
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New drugs to fight cancer are constantly needed. Colon
cancer (bowel cancer) is a cancer caused by uncontrolled
cell growth in the colon, rectum, or vermiform appendix.
It is the third most common cancer and the fourth most
frequent cause of cancer deaths worldwide [1]. Every
year, more than 945000 people develop colorectal cancer
worldwide, and around 492000 patients die [1].
Benzimidazole is a heterocyclic moiety possessing wide
spectrum of biological activities [2]. The biological im-
portance of benzimidazole derivatives is due to their
structural resemblance to the naturally occurring
nucleotides, which allow them to interact with the
biopolymers of the living system [2]. In the last decade
some benzimidazole derivatives have shown some poten-
tial anticancer activities, for example compound 1 exhib-
ited anticancer activity against MCF-7, HL-60, HT-29, and
PD-3 cell lines (IC50 value ranging from 7.0 to 100 μM)
[3]. Compound 2 has shown 51% inhibition of tumor
growth in mice implanted with HT-29 human carcinoma
at 400 mg/kg orally [4]. Compounds 3 and 4 have shown
anticancer (A-549 IC50 2.8 μM, HeLa IC50 5.1 μM) and
antitumor (EBV-EA) activities respectively [5,6].
1 2
3 4
Due to the aforementioned reasons, current study was
conducted to synthesize a series of benzimidazolium salts
(i.e., 9, organic salts) unlike benzimidazole derivatives (i.e.,
1–4, organic compounds) in order to increase the solu-
bility and efficacy of these heterocycles. It was found that
these bis-benzimidazolium salts have shown activity
against human colon cancer cell lines (HCT 116). Azo-
lium (imidazolium, benzimidazolium, triazolium etc.)salts are used as stable precursors to synthesize N-
heterocyclic carbenes (NHCs) and metal complexes [7-9]
(see Figure 1). N-heterocyclic carbenes (NHCs) are types
of carbenes in which a divalent carbon moiety is flanked
by two π-donor nitrogen atoms (for example,5 and 6) [9].
For details see [8,9]
To synthesize NHCs, the more common practice is
substitutions of alkyl/aryl groups at nitrogens of azoles
(imidazole, benzimidazole, triazole etc.) to synthesize
azolium salts in which H-2 hydrogen becomes acidic
which can be removed by addition of a base (e.g., t-
BuOK, NaH etc.) [11,12]. There are numerous ways to
generate free NHCs and their metal complexes [9,13].
Here in this article we report some meta-xylyl linked
bis-benzimidazolium salts of structure 9 with IC50 values
0.1–17.8 μM.
Results and discussions
Most of the naturally occurring and synthetically
available imidazolium or benzimidazolium derivatives
are of the non-bridged variety. It was therefore of
great interest to investigate the addition of an aryl
alkyl spacer of 1,3-dimethylene benzene to such non-
bridged systems to extend the application of direct
electrophilic substitution of long and branched alkyl
chain methodology.
Figure 1 Synthesis of free NHC from benzimidazolium salt and orbital view of a benzimidazolium-based NHC [10].
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All the N-alkyl benzimidazoles were synthesized by
the method developed by starikova et al. [14] with
minor modifications. Furthermore the reaction of
two equivalents of N-alkyl benzimidazole with 1,3-N NH
(i) KOH in DMSO
     stirring at RT
     for 30 min.
(ii) Alkyl halide
      stirring for 2 h








(80 - 100 oC)
12 h
8 R = i-Pr, X = PF6; 9 Pent-2-yl, X = PF6; 1
                     12 Hept, X = B
Step - 1
Step - 2
Scheme 1 Synthesis of N-alkyl benzimidazoles (1-7) and 3,3'-(1,3-phen(bromomethylene)benzene in 1,4-dioxane at 80-100°C
for 24 h afforded the product in 29–94% yield
(Scheme 1).
We have already reported [10,11,13,15-17] the synthe-









0 CH2Ph, X = Cl; 11 Bu, X = PF6; 
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high-yielding, and general synthetic method. We pre-
viously employed ethyl bromide, propyl bromide, i-propyl
bromide, butyl bromide, benzyl chloride, and heptyl
bromide as the electrophiles for 1,2-(bromomethylene)
benzene [17] and now show that the use of these electro-
philes on 1,3-(bromomethylene)benzene is also successful.
The method adopted for the synthesis of title compounds
is selective for the 1-position heterocycle, and the two-
step process is essentially quantitative. Indeed, upon
treating alkylbenzimidazole (1-7) with m-xylyl dibro-
mide (1,3-(bromomethylene)benzene), respective bis-
benzimidazolium salt was observed, to give 8-13 in al-
most quantitative yield. Selected compounds (9. 2Br, 11.
2Br & 12. 2Br) were converted to their respective hexa-
flourophosphate counterparts via metathesis reaction
using KPF6. This step is included for easier handling
and better solubility. The PF6 salts of all the compounds
are soluble in acetonitrile, DMSO, and DMF but not
soluble in methanol, ethanol, and water whereas the
halide salts are soluble in methanol, ethanol, DMSO,
DMF and water but not soluble in acetonitrile.
FT-IR spectra of the compounds
It is of much importance to study the spectral features
in both near and mid IR spectra, for their strong correl-
ation to vibrational structures of the molecules. Repre-
sentative IR spectra of the compounds and the
functional assignments for N-alkylated benzimidazoles
are shown in Figure 2. For all synthesized compounds,
























Figure 2 FT-IR overlay spectrum of N-alkylated benzimidazoles (1-7).3439 cm−1) appeared for the tertiary nitrogen of benzi-
midazolium ring in the observed spectra. The pure
modes of the C-H stretching vibrational bands in both,
alkyl benzimidazoles and bis-benzimidazolium salts
appeared at around 2900 to 3000 cm−1. This variation in
the range is due to presence of C-H (sp3-s) stretching of
alkyl chains and methylene (N-CH2-Ar) group. A strong
and sharp intense band observed in the range 1400
to 1450 cm−1 ascribed to the stretching modes of vibra-
tions of benzimidazole ring due to the presence of -HC=
N- module [18]. It may be concluded that the reduction in
the intensity of this band in benzimidazolium salts is
probably caused by the conjugation of C=N bond with
the benzimidazole ring and due to N-alkylation, where
alkyl group acts as electron donating entity. In benzimida-
zole, the modes due to the ring vibrations are characteris-
tically strong near 1400 and 1460 cm−1 as are absorptions
[19]. The other ring vibrations are intense bands at around
1050 and 1220 cm−1.
FT-NMR spectra of the compounds
FT-NMR spectra of all the compounds have been ana-
lyzed in d6-DMSO and d3-CH3CN over the scan range
0 to 16 δ ppm for 1H NMR and 0 to 200 δ ppm for 13 C
NMR studies. The attachment of N-alkylated benzimida-
zoles (1-7) with 1, 3-(bromomethylene) benzene, to
get final products (8-13), was confirmed by
observing changes in specific chemical shifts for
N-alkylbenzimidazoles and respective salts. For example,
the downfield movement of “Hc” signals for N-CH2-R



















From 4.1 to 4.5  
Appearance of new peak 
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Figure 3 1H NMR spectrum (d6-DMSO, 400 MHz) indicating the changes in chemical shifts after successful reaction (between 6 & 13).
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(acidic proton) from 7.94 to 9.90 respectively. The
appearance of new signal “Hd” at 5.8 for N-CH2-Ar
also supports the attachment of both the reactants
(see Figure 3).
In 13 C NMR spectra peaks appeared between 49 to
56 ppm (see Additional file 2: Table S1). These new sig-
nals confirmed the attachment of m-xylene to respective
N-substituted benzimidazoles (N-CH2-Ar).
In general 1H NMR spectra of all the salts evidenced a
sharp singlet in the range 9.88-10.27 δ ppm ascribed to
the benzimidazolium ring (NCHN) acidic proton. These
signals for imidazole based salts were observed in up
field region, due to the absence of an electron withdraw-
ing phenyl group [10]. Resonances of the aromatic pro-
tons of benzimidazole as well as spacer were observed in
the range 7.38–8.17 δ ppm as a broad multiplet, and
doublet of doublet with comparable coupling constants.
The signals caused by the methylene (N-CH2-Ar) group,
which connects xylyl unit with benzimidazolium units,
display sharp singlets in the range 5.40–5.82 δ ppm. Fi-
nally, the resonance of alkyl protons appeared in the
range 0.80–4.54 δ ppm with comparable coupling con-
stants (see Additional file 2: Table S1).
Similarly, the structural assortments of the salts were
further confirmed by the 13 C NMR spectral technique.
The spectrum of all the salts evidenced a distinguishedpeak in the most down field range 141.81- 143.30 δ ppm
ascribed to the benzimidazolium ring carbon (NCN).
Resonances of aromatic carbons were found in the com-
parable region around 113.86–135.72 δ ppm. Also, the
methylene carbon (N-C-Ar) and alkyl chain carbon reso-
nances were observed in the chemical shift regions
49.83–55.58 and 10.82–51.70 δ ppm, respectively (See
Additional file 2: Table S1).
In addition it is evident that N-C-Ar carbon, in all
cases, is more deshielded as compared to N-C-R carbon
due to being sandwiched by two electron withdrawing
groups because N-C-R group is attached to electron
withdrawing and donor groups (Figure 4).
Crystallography
The molecular structures of the benzimidazolium salts
Additional file 3: 10.2Br and Additional file 4: 13.2PF6
were determined by single crystal X-ray diffraction stu-
dies. The crystals suitable for the diffraction studies
were grown by slow evaporation method. Crystal refine-
ment data, selected bond lengths and angles of salts
Additional file 3: 10.2Br and Additional file 4: 13.2PF6
are tabulated in Tables 1, 2, 3.
Salt Additional file 3: 10.2Br crystallizes in triclinic
space group P-ī with one cationic bis-benzimidazolium
core and two bromide counter ions. Crystal studies re-
veal the existence of salt in a zig-zag manner having
Figure 4 Relative deshielding of methylene groups, attached
directly to benzimidazolium units in NMR spectroscopy.
Table 1 Crystal data and structure refinement details for
compounds 10 and 13
10.Br 13.PF6
Formula C36H32Br2N4 C28H32F12N4P2
Formula Weight 680.48 714.52
Crystal System Triclinic Monoclinic
Space group P ī Cc




α, β, ϒ [deg] 84.963(1), 75.975(1),
87.924(1)
90, 103.064(10), 90





Crystal Size[mm] 0.56 × 0.45 × 0.29 0.58× 0.36 × 0.30
Temperature (K) 90(2) 293(2)
Radiation [Å] MoKa 0.71073 MoKa 0.71073
θ Min – Max [Deg] 1.41 – 28.95 2.11 – 30.070
Dataset −15:15;−15:15;−20 :20 −23:23;−16:16;−22:22
Tot.; Uniq. Data 33351 32572
R(int) 0.0308 0.0225
Nref;Npar 9480; 379 2023; 585
R, wR2, S 0.0472, 0.1376, 1.076 0.0226, 0.1293, 1.029
Table 2 Selected bond lengths and angles of salt 10.2Br
C6-C7 1.513(4) C15-C16 1.515(4) N3-C23 1.331(3)
C7-N1 1.481(3) C16-C21 1.392(4) C23-N4 1.332(4)
N1-C8 1.330(4) C21-C20 1.383(4) N4-C30 1.465(4)
N2-C8 1.339(4) C20-C22 1.516(4) C30-C31 1.511(4)
C15-N2 1.478(3) C22-N3 1.464(3) C21-H21 0.9500
C6-C7-N1 112.0(2) C20-C22-N3 110.7(2)
C7-N1-C8 124.5(2) C22-N3-C23 126.1(2)
N1-C8-N2 110.0(3) N3-C23-N4 109.9(2)
C8-N2-C15 125.0(2) C23-N4-C30 125.6(2)
N2-C15-C16 110.3(2) N4-C30-C31 111.9(3)
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as well as to their own planes. Similarly, the terminal
phenyl groups are perpendicular to the planes of the
benzimidazole rings. However, the shape of the entire
molecule depends on the terminal N-alkyl/aryl substi-
tuent which readily offers the rigidity and finite shape.
The internal imidazole ring angle (N–C–N) at the car-
bene center is 110.0(3)° for N1-C8-N2 and 109.9(2)° for
N3-C23-N4, and these values are well within the range
for similar benzimidazole based salts [16,20,21]. The
bond angles between benzimidazole ring and xylyl were
found to be N2-C9-C14=107.0(4) and N3-C22-C20=110.9
(3) from opposite direction. Similarly, the bond angles of
terminal phenyl ring and benzimidazole were observed in
the similar manner, viz., N1-C7-C6=111.5(4) and N4-
C24-C29= 106.9(4). In the crystal, the bromide anions link
the cations with a three-dimensional network via the
intermolecular hydrogen bonding C-H. . ..Br (2.829 and
3.040 Å) parallel to the bc plane. The contribution of dis-
ordered solvent molecules were removed from thediffraction data with SQUEEZE in PLATON [22,23]. A
perspective view of the salt and its crystal packing are
shown in Figure 5.
On the other hand, salt Additional file 4: 13.2PF6 crystal-
lizes in monoclinic space group Cc having one cationic
bis-benzimidazolium core and two hexafluorophosphate
counter ions. The internal imidazole ring angle at the car-
bene center is 111.0(2)° for N1-C4-N2 and 110.81(18)° for
N3-C25-N4, and these values are well within the range for
similar benzimidazole based salts [16,20,21]. The central
benzene core makes dihedral angles of 111.95(16)° at N1-
Table 3 Selected bond lengths and angles of salt 13.2PF6
C2-C3 1.466(7) C11-C12 1.516(3) N3-C25 1.317(3)
C3-N2 1.508(4) C12-C17 1.382(2) C25-N4 1.338(3)
N2-C4 1.325(4) C17-C16 1.384(2) N4-C26 1.470(3)
C4-N1 1.321(3) C16-C18 1.509(3) C26-C27 1.484(6)
N1-C11 1.468(3) C18-N3 1.474(2) P1-F1 1.506(8)
C2-C3-N2 112.4(4) C16-C18-N3 112.19(15)
C3-N2-C4 132.4(2) C18-N3-C25 126.18(18)
N2-C4-N1 111.0(2) N3-C25-N4 110.81(18)
C4-N1-C11 127.0(2) C25-N4-C26 107.9(9)
N1-C11-C12 111.95(16) N4-C26-C27 113.9(3)
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benzimidazole rings on either side. The extended structure
of the salt evidenced the intermolecular hydrogen bonging
between cationic bis-benzimidazolium core and two hexa-
fluorophosphate anions. The anions link the cations with a
three-dimensional network via the C-H-–F (2.638 and
2.897 Å) hydrogen bonding parallel to the bc plane. A per-
spective view of the salt and its crystal packing are shown
in Figure 6.
Anticancer activity
A wide variety of heterocyclic compounds based on
imidazole, benzimidazole, pyrimidine, pyridine and pu-
rine are being intensively studied as anticancer agents
against various cancer cell lines [24,25]. Furthermore,
imidazole and benzimidazole-based compounds appear
to be very promising candidates for anticancer treat-
ment. As reported in recent reviews there has been aFigure 5 The ORTEP picture of bis-benzimidazolium salt 10.2Br with d
for its Packing (Triclinic).growing interest in the community of synthetic organic
chemistry to examine the anticancer activities of differ-
ent heterocyclic compounds with specific functional
groups [26]. In this perspective, we have designed a
series of bis-benzimidazolium salts with different coun-
ter ions.
The results of the anti-proliferation test using MTT
assay showed that all tested compounds exhibited a dose
dependent effect. Figure 7 shows effect of different con-
centrations of bis-benzimidazolium salts (8-13) on
human colorectal cancer cells (HCT 116) after 72 hours
treatment. Anticancer efficiency of all the tested com-
pounds is tabulated in Table 4. All the tested compounds
demonstrated potent cytotoxicity against HCT 116. In
particular, compounds Additional file 3: 10.2Br and
8.2Br were found to be the most notable examples of
the series with IC50 values 0.1 and 0.2 μM, respectively.
The results showed that the activity of these compounds
was found to be more potent than the standard refer-
ence drug 5-fluorouracil (IC50 = 19.2 μM). Figure 8
shows the picture of cells treated with Additional file 2:
10.2Br for 72 hours. Activity of these compounds is dra-
matically higher than the standard used. Similarly, salts
12.2Br (1.1 μM) and 9.2PF6 (4.1 μM) also exhibited
cytotoxic effect on HCT 116, which was also stronger
than the standard 5-fluorouracil (19.2 μM). In addition,
salts 11.2PF6 and 13
. PF6 also showed significant anti-
proliferation activity with IC50 values 8.7 and 17.6 μM,
respectively, which is more or less equal to 5-FU.
The variation in chain length will affect not only the
solubility of compounds but also influences the cytotoxic
property of the compounds. Thus the results showed theisplacement ellipsoids drawn at 50% probability. See Figure 6A
AB
C
Figure 6 The ORTEP picture of bis-benzimidazolium salt 13.2PF6 with displacement ellipsoids drawn at 50% probability and crystal
packing (Monoclinic).



























Concentrations of Test Samples in µM
13 11 12 10 8 9 5-FU
Figure 7 Anti-proliferation effect of bis-benzimidazolium salts on HCT-116 was assessed by MTT-assay. The figure depicts
dose-dependent activity of all tested compounds. The activity of salts, 8, 9, 10 & 12 was more profound than 5-FU (values are represented as
mean ± SD n=3).
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phenyl and 12.2Br (IC50 = 1.1 μM) with N-heptyl substi-
tutions revealed more potent cytotoxic activity than
the compounds with smaller chain length and non-
aromatic substitutions. In addition, an interesting
phenomenon was noticed with the compounds having
bromide anions (8.2Br, 10.2Br and 12.2Br) demonstrated
significant cytotoxic activity with respect to the com-
pounds (9.2PF6, 11.2PF6 and 13.2PF6) having the hexa-
fluorophosphate anion. This data indicates that the
longer alkyl chain and aromatic substitutions resulted
bis-benzimidazolium salts more efficient compounds
against HCT 116 cells.
Conclusions
In conclusion, a series of bis-benzimidazolium salts was
prepared in two steps. First, the preparation of N-alkyl ben-
zimidazoles by the reaction of benzimidazole with appro-
priate alkyl halide in presence of potassium hydroxide.
Second, the subsequent treatment of N-alkyl benzimidazole
derivatives with 1,3-dibromomethylbenzene in 1,4-dioxaneTable 4 IC50 Values of selected Compounds







5-FU 19.2 μMat refluxing temperature afforded the title compounds in
good yields. Structures of selected salts were established
through single crystal X-ray diffraction technique. All the
synthesized salts were applied against human colon cancer
cell line which showed dose-dependent cytotoxicity. Fur-
thermore, the compounds with either bromide anion or
N-methylene phenyl and N-heptyl substitutions found to
be more potent cytotoxic. Thus, studies on the synthesis
of respective silver complexes to observe the change in




Nuclear magnetic resonance spectra were recorded on
Bruker 400 MHz UltrashieldTM and Bruker Avance
300 MHz spectrometers at ambient temperature. 1 H
and 13 C NMR peaks are labelled as singlet (s), doublet
(d), triplet (t), quartet (q), pentet (pent), sextet (sext),
septet (sept) and multiplet (m), Chemical shifts were
referenced with respect to solvent signals. Elemental
analysis was carried out on a Perkin Elmer series II,
2400 microanalyzer. X-ray diffraction data were taken
with Bruker SMART APEX2 CCD area-detector diffract-
ometer available. The melting and boiling points were
assessed by using a Stuart Scientific SMP-1 (UK) instru-
ment. Chemicals and solvents were used as received
without further purifications. All N-alkyl benzimidazole
compounds were prepared according to the literature
[14] method with slight modifications.
RPMI 1640 was purchased from ScienCell, USA. Tryp-
sin and heat inactivated foetal bovine serum (HIFBS)





IC50 = 0.2 µM 8.2PF6 IC50 = 4.1µM 9.2PF6





Figure 8 HCT116 cell images were taken under an invented phased-contrast microscope at ×200 magnification with a digital camera
at 48 hours after treatment with the samples. A) Cells from the control group showed fully confluent growth. B) Treatment with 8.2PF6
showed marked inhibition in cell proliferation with IC50=0.2μM. The picture revealed the autophagic characteristic in the cells as all cells treated
with 8.2PF6 showed abnormally large number of vacuoles (arrows) in cytoplasm. C) HCT 116 cells treated with the compound 9.2PF6 exhibited
significant cytotoxity (IC50=4.1μM) as the population of cells reduced drastically within the 48 hours of treatment. D) Photomicrograph depicts
the strong cytotoxic effect of 10.2Br (0.1μM). It can be seen clearly that the compound affected the normal morphology of most all the cells of
the group which rendered the cells lose viability. E) Treatment with 11.2PF6 showed the modest inhibition with IC50 8.7μM. F) Treatment with
12.PF6 caused sever death in HCT 116 cells as the cells appeared to be entered in apoptosis by the typhical morphological changes.
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line (PBS), penicillin/streptomycin (PS) solution, MTT
reagent and 5- fluorouracil were purchased from Sigma-
Aldrich, Germany. All other chemicals used in this study
were analytical grade or better.Syntheses
Synthesis of N-substituted benzimidazoles
Synthesis of N-isopropyl benzimidazole (1) Potassium
hydroxide (0.84 g, 0.015 mol) was added to a solution of
benzimidazole (1.4 g, 0.01 mol) in 20 mL of DMSO, the
mixture was stirred for 30 min at 18–20°C, and isopro-
pyl bromide (1.23 g, 0.01 mol) was added dropwise
under vigorous stirring and cooling with a water bath.
After 2 h, the mixture was diluted with 200 ml of water
and extracted with chloroform (6 × 25 ml), the combined
extracts was filtered through 5 plies of whatman filter
papers twice to get crystal clear solution of required
product. The solvent was evaporated under reduced
pressure to collect product as a thick fluid. General reac-
tion involved in the preparation of N-alkyl substituted
benzimidazole is shown in Scheme 1.
Appearance: Yellow oil; Yield: 86%; Boiling point:
184–188°C.FT-IR (liquid) cm−1: 3324 ν (Caliph-Nbenzimi), 3090 and
3066 ν(C-Harom), 2981 and 2955 ν (C-Haliph), 1045 and
1229 ν (Carom-Nbenzimi).
1 H NMR (400 MHz, DMSO-d6) δ ppm: 1.49 (d, 6 H,
2 ×CH3, J= 6.8 Hz), 4.68 (sept, 1 H, i-Pr-CH), 7.18 (pent,
2 H, Ar-H), 7.58 (d, 1 H, Ar-H, J= 8.8 Hz), 7.69 (d, 1 H,
Ar-H, J= 7.2 Hz), 8.29 (s, 1 H, NCHN).
13 C NMR (100 MHz, DMSO-d6) δ ppm: 21.99
(2 ×CH3), 46.95 (i-Pr-CH), 110.29, 119.37, 121.23,
121.99, 132.91 and 141.45 (Ar-C), 143.53 (NCHN).
Synthesis of N-pent-2-ylbenzimidazole (2) Compound
2 was prepared according the same procedure for 1, but
instead of isopropyl bromide, 2-pentyl bromide (1.51 g,
0.01 mol) was added.
Appearance: Colorless liquid; Yield: 77%; Boiling point:
231–232°C.
FT-IR (liquid) cm−1: 3424 ν (Caliph-Nbenzimi), 3084 ν
(C-Harom), 2966 and 2870 ν (C-Haliph), 1052 and 1214 ν
(Carom-Nbenzimi).
1 H NMR (400 MHz, DMSO-d6) δ ppm: 0.75 (t, 3 H,
CH3, J= 7.2 Hz), 1.46 (d, 2 H, CH2, J= 6.8 Hz), 1.72 (m,
5 H, CH3 & CH2), 4.52 (sept, 1 H, CH), 7.15 (pent, 2 H,
Ar-H), 7.59 (d, 1 H, Ar-H, J= 9.6 Hz), 7.64 (d, 1 H, Ar-H,
J= 8.4 Hz), 8.21 (s, 1 H, NCHN).
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19.73 (CH2), 20.98 (CH3), 60.58 (i-Pr-CH), 111.17,
117.68, 120.28, 122.17, 122.85 and 142.14 (Ar-C), 142.82
(NCHN).
Synthesis of N-benzyl benzimidazole (3) Compound 3
was prepared according the same procedure for 1, but
instead of isopropyl bromide, benzyl chloride (1.71 g,
0.01 mol) was added. Compound appeared as white
powder recrystalized by n-hexane/chloroform.
Appearance: Colorless crystals; Yield: 81%; melting
point 84–86°C (Lit. mp 106–108°C [14]).
FT-IR (liquid) cm−1: 3402 ν (Caliph-Nbenzimi), 3077 and
3025 ν (C-Harom), 2937 ν (C-Haliph), 1023 and 1185 ν
(Carom-Nbenzimi).
1 H NMR (400 MHz, DMSO-d6) δ ppm: 5.45 (s, 2 H,
CH2), 7.16 (pent, 2 H, Ar-H), 7.28 (m, 4 H, Ar-H) 7.46
(q, 1 H, Ar-H), 7.64 (t, 1 H, Ar-H, J= 4.6 Hz), 8.38 (s,
1 H, NCHN).
13 C NMR (100 MHz, CH3CN-d3) δ ppm: 48.53 (CH2),
111.56 (Ar-C), 120.38, 122.50 and 123.31 (Ar-C), 128.22,
128.59 and 129.54 (Ar-C), 134.54 (Ar-C), 137.76 (Ar-C),
144.46 (Ar-C), 145.09 (NCHN).
Synthesis of N-butyl benzimidazole (4) Compound 4
was prepared according the same procedure for 1, but
instead of isopropyl bromide, n-butyl bromide (1. 37 g,
0.01 mol) was added.
Appearance: Yellow liquid; Yield: 75.1%; Boiling point:
256–258°C.
FT-IR (liquid) cm−1: 3416 ν (Caliph-Nbenzimi), 3077 ν
(C-Harom), 2959, 2929 and 2863 ν (C-Haliph), 1048 and
1165 ν (Carom-Nbenzimi).
1 H NMR (400 MHz, CD3CN-d3) δ ppm: 0.71 (t, 3 H,
CH3, J= 3.8 Hz), 1.39 (sext, 2 H, CH2), 1.82 (pent, 2 H,
CH2), 4.20 (t, 2 H, N-CH2-R, J=7.2 Hz), 7.09 (pent, 2 H,
Ar-H), 7.38 (d, 1 H, Ar-H, J=2.8 Hz), 7.56 (d, 1 H, Ar-H,
J=2.8 Hz), 7.94 (s, 1 H, NCHN).
13C NMR (100 MHz, CD3CN-d3) δ ppm: 13.20 (CH3),
19.27 (CH2), 31.34 (CH2), 43.77 (N-CH2-R), 109.97, 119.32,
121.18, 122.02, 133.64 and 141.57 (Ar-C), 143.59 (NCHN).
Synthesis of N-heptyl benzimidazole (5) Compound 5
was prepared according the same procedure for 1, but
instead of isopropyl bromide, n-heptyl bromide (1.79 g,
0.01 mol) was added.
Appearance: Yellow liquid; Yield: 88.3%; Boiling point:
246–248°C.
FT-IR (liquid) cm−1: 3424 ν (Caliph-Nbenzimi), 3077 ν
(C-Harom), 2977 and 2856 ν(C-Haliph), 1045 ν(Carom-
Nbenzimi).
1 H NMR (400 MHz, CD3CN-d3) δ ppm: 0.85 (t, 3 H,
CH3, J= 6.8 Hz), 1.22 (m, 8 H, 4 ×CH2), 1.80 (pent, 2 H,CH2, J= 7.2 Hz), 4.13 (t, 2 H, N-CH2-R, J= 7.2 Hz),
7.18–7.26 (m, 3 H, Ar-H), 7.44 (d, 1 H, Ar-H,
J= 9.6 Hz), 7.95 (s, 1 H, NCHN).
13 C NMR (100 MHz, CD3CN-d3) δ ppm: 14.08 (CH3),
22.76, 26.90, 29.00, 30.05 and 31.92 (alkyl chain-C),
45.12 (N-CH2-R), 110.59, 117.57, 120.15, 122.09, 122.93,
134.45 and 134.97 (Ar-C), 144.27 (NCHN).
Synthesis of N-propyl benzimidazole (6) Compound 6
was prepared according the same procedure for 1, but
instead of isopropyl bromide, n-propyl bromide (1.23 g,
0.01 mol) was added.
Appearance: Colourless liquid; Yield: 87.3%; Boiling
point: 236–238°C.
FT-IR (liquid) cm−1: 3402 ν (Caliph-Nbenzimi), 3084 and
3055 ν(C-Harom), 2966, 2929 and 2878 ν (C-Haliph), 1030
and 1211 ν(Carom-Nbenzimi).
1 H NMR (400 MHz, CD3CN-d3) δ ppm: 0.85 (t, 3 H,
CH3, J= 7.35 Hz), 1.82 (sext, 2 H, alkyl chain-CH2), 4.10
(t, 2 H, N-CH2-R, J= 7.05 Hz), 7.25 (m, 2 H, Ar-H), 7.43
(d, 1 H, Ar-H, J= 7.2 Hz), 7.68 (d, 1 H, Ar-H, J= 7.2 Hz),
7.94 (s, 1 H, NCHN).
13 C NMR (100 MHz, CD3CN-d3) δ ppm: 11.05 (CH3),
23.34 (CH2), 46.75 (N-CH2-R), 110.46, 120.22, 122.03,
122.90 and 134.53 (Ar-C), 143.84 (NCHN), 144.2 (Ar-C).
Synthesis of N-ethyl benzimidazole (7) Compound 7
was prepared according the same procedure for 1, but
instead of isopropyl bromide, ethyl bromide (1.23 g,
0.01 mol) was added.
Appearance: Colourless thick liquid; Yield 91%; Boiling
Point: 184–186°C.
FT-IR (liquid) cm−1: 3409 (Caliph-Nbenzimi), 3084 (C-
Harom), 2981, 2929 (C-Haliph), 1037 cm-1 (Carom-
Nbenzimi).
1 H NMR (300 MHz, CD3CN- d3): δ= 1.34 (t, 3 H,
CH3, J= 7.2 Hz), 4.19 (q, 2 H, CH2, J= 7.35 Hz), 7.18
(pent, 2 H, Ar-H), 7.47 (d, 1 H, Ar-H, J= 9.9 Hz), 7.65
(d, 1 H, Ar-H, J= 9.9 Hz), 8.24 (s, 1 H, NCHN).
13 C NMR (75 MHz, DMSO-d6): δ= 14.59 (CH3),
38.79 (N-CH2-R), 109.57, 119.17, 120.97, 121.80, 134.52,
142.70 (Ar-C), 143.68 (NCHN).
Synthesis of N-substituted bis-benzimidazolium salts
Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-isopropyl-
benzimidazolium) dibromide (8.2PF6)
N-isopropyl benzimidazole (1) (3.2 g, 0.02 mol) was
added drop wise in a vigorously stirring solution of 1,3-
dibromomethyl benzene (2.64 g, 0.01 mol) in 50 ml of
1,4-dioxane and refluxed for 24 h. The product settled
as a sticky brownish viscous oil at the bottom of flask,
than the upper layer was decanted and product was
washed with fresh dioxane (3× 5 ml). The resulting bro-
mide salt was converted directly to its hexaflourophosphate
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in 50 mL of methanol. The mixture was stirred for 24 h
and filtered. The white precipitates were collected and
washed with distilled water (2× 5 mL), then left to dry at
ambient temperature. General reaction involved in the
preparation of N-alkyl substituted bis-benzimidazolium
salts is shown in Scheme 1. The bromide salt of title com-
pound was used for anticancer study.
Appearance: White powder; Yield: 70.1%; Melting
point: 165-168°C.
FT-IR (solid): 3431 (Caliph-Nbenzimi), 3166, 3099 (C-
Harom), 2981, 2858, 2828 (C-Haliph), 1048, 1133,
1203 cm-1 (Carom-Nbenzimi).
1 H NMR (400 MHz, DMSO-d6): δ= 1.64 (d, 6 H,
2 ×CH3, J= 6.8 Hz), 5.05 (hept, 2 H, i-Pr 2 ×CH,
J= 6.6 Hz), 5.75 (s, 4 H, 2 ×N-CH2-Ar), 7.42-7.70 (br.m,
8 H, Ar-H), 7.78 (d, 2 H, Ar-H, J= 8.4 Hz), 8.12 (d, 2 H,
Ar-H, J= 8.40), 10.03 (s, 2 H, 2 ×NCHN).
13 C NMR (100 MHz, DMSO-d6): δ= 22.28 (CH3),
50.65 (CH2), 51.70 (i-Pr-CH), 114.58, 115.02 (Ar-C),
127.48, 127.53, 129.32, 131.57, 131.77, 135. 60 (Ar-C)
and 141.80 (NCHN).
Anal. Calcd for C28H32F12N4P2: C, 47.07; H, 4.51; N,
7.84. Found: C, 46.92; H, 4.48; N, 7.55.
Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-(pentan-
2-yl)-benzimidazolium) bis(hexaflourophosphate) (9.2PF6)
Compound 9.2PF6 was prepared according to the same
procedure for 8.2PF6, but instead of 1, compound 2
(3.76 g, 0.02 mol) was added.
Appearance: White powder; Yield: 29.4%; Melting
point: 182–184°C.
FT-IR (solid): 3431 (Caliph-Nbenzimi), 3151, 3092 (C-
Harom), 2959, 2870 (C-Haliph), 1052, 1111, 1192 cm-1
(Carom-Nbenzimi).
1 H NMR (300 MHz, DMSO-d6): δ= 0.88 (t, 6 H,
2 ×CH3, J= 7.5 Hz), 1.24 (m, 2 H, CH2), 1.63 (m, 2 H,
CH2), 1.97 (m, 2 H, CH2), 2.36 (s, 10 H, CH3 and CH2),
4.96 (sept, 2 H, CH), 5.40 (d, 4 H, N-CH2-Ar,
J= 11.7 Hz), 7.46–8.17 (br.m, 12 H, Ar-H), 10.16 (d, 2 H,
2 ×NCHN, J= 13.8 Hz).
13 C NMR (75 MHz, DMSO-d6): δ= 14.31 (CH3),
19.42 (CH2), 20.66 (CH3), 38.20 (CH2), 50.70 (pent-2-yl
CH), 55.58 (N-CH2-Ar), 114.18 (Ar-C), 127.58, 129.32,
129.50, 130.62, 131.7 (Ar-C), and 135.56, 135.75
(NCHN).
Anal. Calcd for C32H32F12N4P2: C, 49.87; H, 5.23; N,
7.27. Found: C, 49.34; H, 5.19; N, 7.12.
Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-benzyl-
benzimidazolium) dibromide (10.2Br)
Compound 3 (4.16 g, 0.02 mol) was added drop wise in
a vigorously stirring solution of 1,3-dibromomethylene
benzene (0.01 mol) in 50 ml of 1,4-dioxane and refluxedfor 24 h. The product precipitated after completion of
the reaction, the solution was filtered to collect the sus-
pended material, washed with fresh 1,4-dioxane
(3 × 5 mL). The beige coloured lumps were air dried for
24 h and ground to fine powder. In this case, the bro-
mide salt is stable and hence there is no need for the
conversion into PF6 salt.
Appearance: beige colored solid; Yield: 51.7%; Melting
point: 120–123°C.
FT-IR (solid): 3409 (Caliph-Nbenzimi), 3121, 3025 (C-
Harom), 2959 (C-Haliph), 1015, 1185 cm-1 (Carom-
Nbenzimi).
1 H NMR (300 MHz, CD3CN-d3): δ= 5.74 (s, 4 H,
2 ×CH2), 5.78 (d, 4 H, 2 ×CH2, J= 4.00 Hz), 7.38-7.98
(br.m, 22 H, Ar 22 ×CH), 10.18 (s, 2 H, 2 ×NCHN).
13 C NMR (100 MHz, CD3CN-d3): δ= 51.11, 51.34
(CH2), 68.2 (CH2), 117.2 (CH), 119.5 (CH), 128.4 –
135.9 (Ar-C), 142.3 (NCHN).
Anal. Calcd for C36H32Br2N4: C, 63.54; H, 4.74; N,
8.23. Found: C, 63.15; H, 4.68; N, 8.16.Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-butyl-
benzimidazolium) bis(hexaflourophosphate) (11.2PF6)
Compound 11.2PF6 was prepared according to the same
procedure for 8.2PF6, but instead of 1, compound 4
(3.48 g, 0.02 mol) was added.
Appearance: White solid; Yield: 46.5%; Melting point:
230–233°C.
FT-IR (solid): 3439 (Caliph-Nbenzimi), 3158, 3099 (C-
Harom), 2929, 2959, 2870 (C-Haliph), 1052, 1111,
1203 cm-1 (Carom-Nbenzimi).
1 H NMR (400 MHz, DMSO-d6): δ= 0.95 (t, 6 H,
2 ×CH3, J= 5.6 Hz), 1.39 (m, 4 H, 2 ×CH2), 1.92 (m,
4 H, 2 ×CH2), 4.50 (t, 4 H, 2 ×N-CH2-R, J= 7.2 Hz),
5.75 (s, 4 H, 2 ×N-CH2-Ar), 7.46-7.80 (br.m, 12 H, Ar-H),
9.83 (s, 2 H, 2 ×NCHN).
13 C NMR (100 MHz, DMSO-d6): δ= 14.14 (CH3).
19.93 (CH2), 31.28, 47.51 (CH2), 50.64, 50.83 (N-CH2-
Ar), 114.52, 114.69 (Ar-C), 127.58, 129.32, 130.71,
132.22, 135.5 (Ar-C), 143.20 (NCHN).
Anal. Calcd for C30H36F12N4P2: C, 48.52; H, 4.89; N,
7.55. Found: C, 48.13; H, 4.48; N, 7.34.Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-heptyl-
benzimidazolium) dibromide (12.2Br)
Compound 12.2Br was prepared according to the same
procedure for 10.2Br, but instead of compound 3, com-
pound 5 (4.32 g, 0.02 mol) was added.
Appearance: Light brown coloured powder; Yield:
93.5%; Melting point: 249–251°C.
FT-IR (solid): 3416 (Caliph-Nbenzimi), 3121, 3011 (C-
Harom), 2922, 2848 (C-Haliph), 1008, 1214 cm-1 (Carom-
Nbenzimi).
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2 ×CH3, J= 6.6 Hz), 1.22-1.32 (br.d, 16 H, alkyl chain
8 ×CH2, J= 29.7 Hz), 1.94 (pent, 4 H, 2 ×CH2), 4.54 (t,
4 H, 2 ×N-CH2-R, J= 7.35 Hz), 5.82 (s, 4 H, 2 ×N-CH2-
Ar), 7.45-7.68 (br.m, 8 H, Ar-H), 7.92 (d, H, Ar-CH,
J= 8.1 Hz), 7.93 (d, 2 H, Ar-H, J= 8.4 Hz), 10.27 (s, 2 H,
2 ×NCHN).
13 C NMR (75 MHz, DMSO-d6): δ= 10.02 (CH3),
13.46, 18.57, 19.82, 26.50, 37.24 (alkyl chain 5 ×CH2),
49.85 (N-CH2-R), 54.37 (N-CH2-Ar), 114.20 (Ar-C),
126.74, 128.48, 128.66, 129.77, 130.88, 130.95, 134.71,
134.90 (Ar-C), 141.40, 143.08 (NCHN).
Anal. Calcd for C36H48Br2N4: C, 62.07; H, 6.95; N,
8.04. Found: C, 61.70; H, 6.72; N, 7.97.
Synthesis of 3,3'-[1,3-phenylene(methylene)]bis(1-propyl-
benzimidazolium) bis(hexaflourophosphate) (13.2PF6)
Compound Additional file 4: 13.2PF6 was prepared
according to the same procedure for 8.2PF6, but instead
of 1, compound 6 (3.2 g, 0.02 mol) was added. For
characterization see [10].
In vitro Anticancer activity
Preparation of cell culture
Initially, HCT 116 cells were allowed to grow under op-
timal incubator conditions. Cells that had reached a con-
fluence of 70-80% were chosen for cell plating purposes.
Old medium was aspirated out of the plate. Next, cells
were washed using sterile phosphate buffered saline
(PBS) (pH 7.4), 2-3 times. PBS was completely discarded
after washing. Following this, trypsin was added and dis-
tributed evenly onto cell surfaces. Cells were incubated
at 37°C in 5% CO2 for 1 min. Then, the flasks containing
the cells were gently tapped to aid cells segregation and
observed under inverted microscope (if cells segregation
is not satisfying, the cells will be incubated for another
minute) Trypsin activity was inhibited by adding 5 ml of
fresh complete media (10% FBS). Cells were counted
and diluted to get a final concentration of 2.5 × 105 cells/
mL, and inoculated into wells (100 μL cells/well). Finally,
plates containing the cells were incubated at 37°C with
an internal atmosphere of 5% CO2.
MTT assay
Cancer cells (100 μL cells/well, 1.5 × 105 cells/mL) were
inoculated in wells of microtitre plate. Then the plate
was incubated overnight in CO2 incubator in order to
allow the cell for attachment. 100 μL of test substance
were added into each well containing the cells. Test sub-
stance was diluted with media into the desired concen-
trations from the stock. The plates were incubated at 37°C
with an internal atmosphere of 5% CO2. After 72 hours
treatment period, 20 μL of MTT reagent was added intoeach well and incubated again for 4 hours. After this incu-
bation period, 50 μL of MTT lysis solution (DMSO) was
added into each well. The plates were further incubated
for 5 min in CO2 incubator. Finally, plates were read at
570 and 620 nm wavelengths using a standard ELISA
microplate reader. Data were recorded and analyzed
for the assessment of the effects of test substance on cell
viability and growth inhibition. The percentage of growth
inhibition was calculated from the optical density (OD)
that was obtained from MTT assay. 5-FU was used as the
standard reference drug.
Additional files
Additional file 1: Labelled Spectra (NMR & FT-IR).
Additional file 2: Table S1. Some characteristic signals of
bis-benzimidazolium salts in NMR Spectroscopy.
Additional file 3: CIF file of 10. 2Br.
Additional file 4: CIF file 13.2PF6.
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